Reckitt Benckiser adds addiction products

Arbaclofen placarbil could be marketed to over 140million people worldwide.

Also: Reckitt Benckiser Group’s pharmaceuticals unit will develop and sell XenoPort Inc’s drug to treat alcohol-use disorders.